Home Newsfeeds Stifel Maintains Hold on VF, Lowers Price Target to $35

Stifel Maintains Hold on VF, Lowers Price Target to $35

Stifel analyst Jim Duffy maintains VF (NYSE:VFC) with a Hold and lowers the price target from $43 to $35.

byBenzinga Newsdesk

September 29, 2022

1 minute read

Stifel analyst Jim Duffy maintains VF (NYSE:VFC) with a Hold and lowers the price target from $43 to $35.

Genasys Inc. Expands Critical Communications Coverage In San Diego County With New Zonehaven Contract

By Happy Mohamed

March 30, 8:46 AM

Genasys Inc. (NASDAQ: GNSS), the global leader in critical communications systems and solutions that help keep people safe, today announced a new multi-year Zonehaven evacuation management

GNSS

$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today

By Benzinga Insights

October 30, 4:30 PM

Air Products & Chemicals (NYSE:APD) has outperformed the market over the past 10 years by 1.82% on an…

APD

Former Ford CEO Sees A Bright Electric Future For Established Automakers, Says They Are ‘Well Positioned To Ride Out The Transition’

By Benzinga Neuro

March 28, 2:24 AM

He added that the automakers' stronghold in the internal combustion (ICE) vehicle business combined with a large installed base is helping them gain investors trust, despite high labour costs.

HC Wainwright Sees Agile Therapeutics’ Twirla Tailwinds Post Roe-Wade Ruling

By Vandana Singh

July 12, 2:33 PM

Agile Therapeutics Inc's (NASDAQ: AGRX) Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that legalized abortion nationwide.

AGRX

Stifel Maintains Hold on VF, Lowers Price Target to $35

Related Posts

Genasys Inc. Expands Critical Communications Coverage In San Diego County With New Zonehaven Contract

$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today

Former Ford CEO Sees A Bright Electric Future For Established Automakers, Says They Are ‘Well Positioned To Ride Out The Transition’

HC Wainwright Sees Agile Therapeutics’ Twirla Tailwinds Post Roe-Wade Ruling